PsyArXiv
May 27, 2026
Andrew Robert Gallimore, Niffe Hermansson, Donald D Hoffman
preprint
Encounters with apparently autonomous and intelligent non-human entities are a striking and recurrent feature of high-dose N,N-dimethyltryptamine (DMT) experi-ences. Such encounters are typically interpreted as complex hallucinations derived from internally generated brain activity, although many features of the DMT state remain a challenge to explain within the standard neuroscientific...
Journal of psychopharmacology (Oxford, England)
May 23, 2026
Joanna Kuć, Rosalind McAlpine, Amelia Sellers et al.
5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a potent, short-acting psychedelic, induces profound shifts in cognition, affect, and self-awareness. Because language explicitly expresses these domains and voice implicitly conveys them, both may serve as potential 'biomarkers' of behavioural change. This study introduces a novel framework for analysing baseline language and vocal features, pre-...
Research Square
May 20, 2026
Isabel Wießner, Marcelo Falchi-Carvalho, Sophie Laborde et al.
DMT, Madness, and Healing: Psychosis Model, Therapy Model, and Their Relations to Mystical Experiences and Positive Emotionality
DIGITAL.CSIC (Spanish National Research Council (CSIC))
May 12, 2026
Javier Calleja‐conde, Víctor Echeverry‐alzate, Marina Sanz-Sancristóbal et al.
Parkinson's disease is a progressive neurodegenerative disorder with increasing global prevalence, primarily driven by population ageing. A hallmark of the disease is the degeneration of nigrostriatal dopaminergic neurons, accompanied by marked activation of glial cells and a sustained neuroinflammatory response. Current pharmacological treatments are limited to symptomatic relief and do not...
bioRxiv Preprint Server
May 5, 2026
Povilas Tarailis, Inga Griškova-bulanova
preprint
Electroencephalographic (EEG) microstates provide a compact framework for characterizing the temporal organization of large-scale brain activity, yet their sensitivity to altered brain states remains insufficiently explored. In this study, we applied broadband and frequency-resolved EEG microstate analysis to resting-state EEG data from two publicly available datasets acquired under markedly...
bioRxiv
May 4, 2026
Tomás Ariel D’amelio, Tomás Gil Garbagnoli, Jerónimo Rodríguez Cuello et al.
ABSTRACT Serotonergic psychedelics induce altered states of consciousness characterised by profound changes in emotional experience. Although psychedelics modulate autonomic arousal, sympathetic engagement during their affective effects remains poorly characterised. We recorded cardiac, electrodermal, and respiratory activity in 19 participants following inhalation of 20 or 40 mg of freebase...
Journal of psychopharmacology (Oxford, England)
May 2, 2026
Zarmeen Zahid, Rick J. Strassman, Clifford Qualls et al.
Serotonergic psychedelics are being investigated in the treatment of various disorders and in the improvement of well-being. Evidence suggests that their subjective effects may play a role in long-term behavioral outcomes. The subjective effects are mediated by 5-HT2A receptor agonism, but the 5-HT1A receptor may also play a role in the subjective effects. This study elucidates the effects of...
European Stroke Journal
May 1, 2026
Anna Zsigmond, Rita Frank, Botond Eröss et al.
Abstract Background and aims Spreading depolarizations (SDs) exacerbate neuronal injury during acute ischemic stroke (AIS). The sigma-1 receptor (S1R) agonist dimethyltryptamine (DMT) reduces cellular damage, inhibits SDs, and enhances neuronal survival in rodent models of AIS. Although DMT primarily acts on S1R, it also binds to aminergic receptors. Therefore, we aimed to determine the...
Sleep
May 1, 2026
Denise C. Vidot, Bria-Necole Diggs, Amrit Baral et al.
Abstract Introduction Psychedelic use and interest in its therapeutic potential are rapidly increasing; yet its relationship with insomnia remains poorly understood. This study aims to estimate differences in insomnia severity by type of psychedelic consumed among a cohort of 18-to-35-year olds. Methods Data are from the Herbal Heart Study - Sleep Ancillary (N=100) cannabis consumers....
Journal of Neurochemistry
May 1, 2026
Jannik Nicklas Eliasen, Amir Rezagholizadeh, Helene Påbøl Jacobsen et al.
ABSTRACT Depression and substance use disorder (SUD) affect millions globally and unfortunately, while established treatments exist, they are not always adequate. Psychedelics have emerged as a promising avenue for development of more effective pharmacological interventions. Dimethyltryptamine (DMT), a classic psychedelic, has shown anti‐depressive and anti‐addictive properties in preclinical...